Evidence map›Paper›PMID 36681780›Full record

ArticleCell death and differentiation2023

Cell differentiation modifies the p53 transcriptional program through a combination of gene silencing and constitutive transactivation.

Roubina Tatavosian, Micah G Donovan, Matthew D Galbraith, Huy N Duc, Maria M Szwarc, Molishree U Joshi, Amy Frieman, Ganna Bilousova, Yingqiong Cao, Keith P Smith and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Cell death and differentiation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. iScience · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Roubina TatavosianDepartment of Pharmacology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Micah G DonovanDepartment of Pharmacology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Matthew D GalbraithDepartment of Pharmacology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Huy N DucFunctional Genomics Facility, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Maria M SzwarcDepartment of Pharmacology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Molishree U JoshiFunctional Genomics Facility, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Amy FriemanCharles C. Gates Center for Regenerative Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Ganna BilousovaCharles C. Gates Center for Regenerative Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Yingqiong CaoDivision of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Keith P SmithLinda Crnic Institute for Down Syndrome, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Kunhua SongDivision of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Angela L RachubinskiLinda Crnic Institute for Down Syndrome, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Zdenek AndrysikDepartment of Pharmacology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA. zdenek.andrysik@cuanschutz.edu.
Joaquin M EspinosaDepartment of Pharmacology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA. joaquin.espinosa@cuanschutz.edu.ORCID http://orcid.org/0000-0001-9048-1941
University of Colorado Anschutz Medical Campus · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Stress- and Promoter-Specific Mechanisms of Transcritpional Activation by p53R01CA117907 · NCI · UNIVERSITY OF COLORADO DENVER · PI ESPINOSA, JOAQUIN M. · 2006 to 2022
$4.4M
Mechanisms for cell signaling in the control of cardiomyogenesisR01HL133230 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI Kunhua Song · 2016 to 2026
$4.2M
Regulation of gene transcription and alternative splicing by a long non-coding RNAR01HL159086 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI SONG, KUNHUA, VONDRISKA, THOMAS M. · 2022 to 2025
$2.1M
NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA117907NHLBI NIH HHS R01 HL133230NHLBI NIH HHS R01 HL159086
6 · The paper itself

Abstract

The p53 transcription factor is a master regulator of cellular responses to stress that is commonly inactivated in diverse cancer types. Despite decades of research, the mechanisms by which p53 impedes tumorigenesis across vastly different cellular contexts requires further investigation. The bulk of research has been completed using in vitro studies of cancer cell lines or in vivo studies in mouse models, but much less is known about p53 action in diverse non-transformed human tissues. Here, we investigated how different cellular states modify the p53 transcriptional program in human cells through a combination of computational analyses of publicly available large-scale datasets and in vitro studies using an isogenic system consisting of induced pluripotent stem cells (iPSCs) and two derived lineages. Analysis of publicly available mRNA expression and genetic dependency data demonstrated wide variation in terms of expression and function of a core p53 transcriptional program across various tissues and lineages. To monitor the impact of cell differentiation on the p53 transcriptome within an isogenic cell culture system, we activated p53 by pharmacological inhibition of its negative regulator MDM2. Using cell phenotyping assays and genome wide transcriptome analyses, we demonstrated that cell differentiation confines and modifies the p53 transcriptional network in a lineage-specific fashion. Although hundreds of p53 target genes are transactivated in iPSCs, only a small fraction is transactivated in each of the differentiated lineages. Mechanistic studies using small molecule inhibitors and genetic knockdowns revealed the presence of two major regulatory mechanisms contributing to this massive heterogeneity across cellular states: gene silencing by epigenetic regulatory complexes and constitutive transactivation by lineage-specific transcription factors. Altogether, these results illuminate the impact of cell differentiation on the p53 program, thus advancing our understanding of how this tumor suppressor functions in different contexts.

Indexed as

NeoplasmsTumor Suppressor Protein p53AnimalsCell DifferentiationGene SilencingHumansMiceTranscriptional ActivationTranscription FactorsTranscription FactorsTumor Suppressor Protein p53

Identifiers

PMID36681780
PMCPMC10070495
OpenAlexW4317659805

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.